Olympus shares plunge 13% after FDA warning letter on six facilities

On October 14, 2026, shares of Olympus Corp. fell up to 17% after the U.S. Food and Drug Administration issued a warning letter over quality management failures at six facilities in the U.S., Japan, and Europe. The $12.4 billion medical technology company stated the warning would not affect production or financial results, promising a response within 15 business days. The regulatory rebuke deepens compliance issues ongoing since 2022 and increases vulnerability to private equity takeovers despite CEO Bob White's turnaround efforts.

Olympus shares drop significantly

• ▪Olympus Corp. shares settled down 13.2% on October 14, 2026, leaving the stock down 13.3% since the start of 2026
• ▪Olympus Corp. previously suffered a major single-day stock decline in 2011 after admitting to an accounting scandal
• ▪Olympus Corp. shares fell up to 17% in Tokyo on October 14, 2026, marking their largest single-day drop since 2011

FDA issues warning letter to Olympus

• ▪The U.S. Food and Drug Administration issued a warning letter to Olympus Corp. following quality management inspections conducted at six facilities in late 2025
• ▪The U.S. Food and Drug Administration warning letter issued on October 14, 2026 rebuked Olympus Corp.'s quality management system across six factories in the U.S., Japan, and Europe

Olympus responds to warning letter

• ▪Olympus Corp. Chief Executive Bob White stated the company takes the U.S. Food and Drug Administration's concerns in its October 14, 2026 warning letter seriously and is committed to resolving them with urgency
• ▪Olympus Corp. stated it will submit a comprehensive response to the U.S. Food and Drug Administration warning letter issued on October 14, 2026 within 15 business days of receipt
• ▪Olympus Corp. stated in an October 13, 2026 filing that the U.S. Food and Drug Administration warning letter issued on October 14, 2026 will not disrupt production or impact financial results

Analyst assesses quality management issues

• ▪Jefferies analyst Stephen Barker stated that the U.S. Food and Drug Administration warning letter issued on October 14, 2026 confirms quality management issues at Olympus Corp. are systemic
• ▪Jefferies analyst Stephen Barker stated that full resolution of quality management issues at Olympus Corp.'s six facilities is expected to take longer because more of its facilities are now under warning letters

Debatable claims

• ▪Olympus's quality control failures represent a systemic operational breakdown
• ▪The FDA's multi-facility warning letters were a proportional response to recurring compliance flaws